Protect Your Rights
Contact Our Lawyers
for a free consultation
toll free (866) 761-1385
or tell us about yourself below
Ortho-McNeil-Janssen is a subsidiary of Johnson & Johnson.
The division was formed by merging Ortho-McNeil Pharmaceutical, and Janssen Pharmaceutica. The Ortho-McNeil branch is focused on infectious disease treatment and as such, developed Levaquin for treatment of infections.
The parent company, Johnson & Johnson (J&J), provides a large number of items to consumers, medical devices, diagnostic devices, and prescription products. Some of the products produced by J&J are moisturizers, contact lenses, and glucose management systems in addition to prescription medications. J&J was founded in 1886 and was incorporated in 1887. It was family-owned until 1944. J&J employs more than 117,000 people in over 250 companies worldwide. Pharmaceutical departments focus on neuroscience, cardiovascular disease, immunology, infectious disease, and oncology. In 2008, J&J worldwide sales were $63.7 billion. Last year, Levaquin was responsible for $1.6 billion in revenue.Do You Have A Levaquin Antibiotic Case? »
Johnson & Johnson is now faced with lawsuits from consumers that inadequate warnings were given in regards to the most serious side effects of the drug Levaquin. J&J and its Ortho-McNeil Pharmaceutical branch promoted Levaquin as a safe medication that was uniquely effective in the treatment of upper respiratory, skin, and urinary tract infections. The lawsuits claim that the companies were aware of the dangers of tendonitis and tendon rupture, yet minimized these adverse effects in communications with prescribing physicians.
In July of 2008, the US Food and Drug Administration (FDA), ordered the company to utilize the black box warning to caution patients about the possibility of severe side effects to tendons. The black box warning is the most serious warning that the FDA can require drug makers to use. Based on increasing numbers of consumer complaints of painful tendon inflammation and rupture, the FDA response was appropriate and welcome. The multi-billion dollar pharmaceutical company now prints the black box warning on prescribing and patient documentation for Levaquin. The "black box" stands for the bold outline surrounding the serious information, calling attention to it as extremely important to read.
J&J and its subsidiaries will face the consumers who sustained injuries related to the use of Levaquin when it was inadequately labeled for dangers. The MDL is in the preliminary stages now and experts project that the first trials will begin in January of 2010.Contact Our Levaquin Lawyers Today »
If you, or someone you know, has suffered from tendonitis or rupture related to Levaquin use, please contact a lawyer today.